Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2021

View Archived Issues

4-PBA and TUDCA reduce symptoms in murine model of Alport syndrome

ADAMTS15 genetic variation causes hand and feet contractures without palmar creases

Neurons derived from iPSCs capture encoded genetic risk for Alzheimer's disease

New DGAT-2 inhibitors discovered at Inorbit Therapeutics

Boehringer Ingelheim describes new plasma kallikrein inhibitors

Monoglyceride lipase inhibitors identified at Janssen

Curadev Pharma presents new STING antagonists

Anti-VISTA antibody PMC-309 shows antitumor activity in vivo

ZEN-3694 reverses acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

AI-driven discovery of novel candidates for idiopathic pulmonary fibrosis

IL-21 and IL-6 predict clinical worsening in patients with COVID-19

Analysis boosts genomics-driven precision medicine

Discovery of novel new anti-cryptosporidial lead, SLU-2633

NeuExcell, Spark Therapeutics enter collaboration to develop gene therapy for Huntington's disease

CRP, ferritin and D-dimer as biomarkers for predicting COVID-19 pneumonia progression

BCL7A predicts outcome in glioma patients

In vitro lung models of COVID-19 developed using stem cell-derived human lung organoids

Insilico Medicine and University of Cambridge collaborate on protein liquid-liquid phase separation

Adaptimmune and Genentech collaborate on allogeneic cell therapies for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...